Appetite‑gene Effects Quantified
- Researchers reported a GLP‑1 receptor variant, rs10305420, adds about 0.76 kg extra loss per allele during treatment. (x.com) - They also flagged GIPR variant rs1800437 as increasing tirzepatide vomiting risk (OR≈1.83), with large combined‑risk effects reported. (x.com) - Those specific variants are being discussed as part of precision models to predict who gets benefit versus side effects. (x.com)
Weight-loss shots act on gut-hormone switches that curb appetite and slow stomach emptying, but people taking the same drug often lose very different amounts of weight. A Nature study published April 8 traced part of that gap to DNA differences in the drug targets themselves. (nature.com) Researchers analyzed self-reported treatment response in 27,885 people who had used glucagon-like peptide 1 drugs, including semaglutide and tirzepatide. They found a GLP1R variant, rs10305420, linked to about 0.76 kilograms of extra weight loss for each copy of the effect allele. (nature.com) They also found side-effect signals in genes tied to the same pathway. Variation in GLP1R and in GIPR, a second receptor targeted by tirzepatide, was associated with nausea or vomiting, and the GIPR signal appeared only in people using tirzepatide. (nature.com) In plain terms, the study points to receptor genes as part of the reason one patient responds like a “super-responder” while another stops because of stomach symptoms. A Nature News analysis said the variants offer clues to who might get more benefit and who might face adverse effects. (nature.com) The drugs involved already list gastrointestinal problems as common side effects. The current U.S. prescribing information for Zepbound says nausea, diarrhea and vomiting are among the most common adverse reactions, and Wegovy’s label lists the same cluster. (fda.gov 1) (fda.gov 2) The paper did not say genes alone determine outcomes. Outside experts told the Science Media Centre that the genetic effects looked biologically plausible but small in clinical terms, with sex, drug choice, dose and treatment duration explaining more of the variation overall. (sciencemediacentre.org) Those experts also pointed to limits in the data. The main analysis relied on 23andMe participants’ self-reported weight loss, treatment duration and side effects, and the cohort was predominantly female and largely of European ancestry. (sciencemediacentre.org) Even so, the authors built combined models using genetic and non-genetic factors and reported that those models could sort patients by likely efficacy and side-effect risk. That is the near-term use case: not a stand-alone DNA verdict, but another input into choosing and managing obesity treatment. (nature.com) The immediate takeaway is narrower than the hype around “personalized” weight-loss medicine. The strongest new evidence is that common variants in GLP1R and GIPR measurably nudge both benefit and tolerability, while most of the outcome still depends on the drug, the dose and the patient in front of the clinician. (nature.com) (sciencemediacentre.org)
